Page 68 - 2020_01-Haematologica-web

B. Dholaria et al.
67. Cauchois R, Castagna L, Pagliardini T, et al.
Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haemato- logical malignancies: a retrospective bicen- tric analysis of serial infusions of increasing doses of CD3(+) cells. Br J Haematol. 2019;185(3):570-573.
68. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplanta- tion for chronic myeloid leukemia. Blood. 2000;96(8):2712-2716.
69. Yan CH, Liu DH, Xu LP, et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell trans- plantation: incidence and risk factors. Clin Transplant. 2012;26(6):868-876.
70. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica. 2004;89(12):1517-1524.
71. Wen Q, Kong Y, Zhao HY, et al. G-CSF- induced macrophage polarization and mobi- lization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(9):1419-1433.
72. Chen SH, Li X, Huang XJ. Effect of recombi- nant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol. 2004;79(2):178-184.
73. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization poten- tial of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G- CSF primed bone marrow grafts in different proportions. Transpl Immunol. 2007;17(3): 193-197.
74. Gómez-De León A, Colunga Pedraza PR, Garcia-Camarillo DE, et al. Donor Lymphocyte Infusion from G-CSF-Primed, Unmanipulated Whole Blood Is Safe and Improves Chimerism in HLA-Matched and Haploidentical Transplantation. Blood. 2018;132(Suppl 1):4602.
75. Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007;13(2 Pt 1):644-653.
76. He F, Warlick E, Miller JS, et al. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is asso- ciated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 2016;51(8): 1107-1112.
77. Goodyear O, Agathanggelou A, Novitzky- Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908-1918.
78. Guillaume T, Yakoub-Agha I, Tabrizi R, et al. Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 2016; 128(22):1162.
79. Schroeder T, Rautenberg C, Haas R, Kobbe G. Hypomethylating agents after allogeneic
blood stem cell transplantation. Stem Cell
Investig. 2016;3:84.
80. Schroeder T, Czibere A, Platzbecker U, et al.
Azacitidine and donor lymphocyte infu- sions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229- 1235.
81. Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicen- ter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2018;97(2):335-342.
82. Bazarbachi A, Labopin M, Battipaglia G, et al. Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clin Hematol Int. 2019;1(1):58-74.
83. Canaani J. Management of AML Beyond “3 + 7” in 2019. Clin Hematol Int. 2019;1:10-18. 84. Schmidt SA, Holter Chakrabarty J, Liu Y, et al. Tyrosine Kinase Inhibitors with or with- out Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation. Blood.
2018;132(Suppl 1):704.
85. Vago L, Perna SK, Zanussi M, et al. Loss of
mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361 (5):478-488.
86. Crucitti L, Crocchiolo R, Toffalori C, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mis- matched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29(5):1143-1152.
87. Imus PH, Blackford AL, Bettinotti M, et al. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1887- 1894.
88. McCurdy SR, Iglehart BS, Batista DA, et al. Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses after Haploidentical Bone Marrow Transplantation with Posttransplantation Cyclophosphamide. Leukemia. 2016;30(10): 2102-2106.
89. Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynam- ics and clinical implications. Blood. 2018;131(2):247-262.
90. Jaiswal SR, Bhakuni P, Bharadwaj P, et al. CTLA4Ig Primed Donor Lymphocyte Infusions (DLI): A Novel Approach to Natural Killer Cell Immunotherapy Following Haploidentical PBSC Transplantation for Advanced Hematological Malignancies. Blood. 2017; 130(Suppl 1):4468.
91. Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expand- ed donor-derived NK cells after haploidenti- cal transplantation. Blood. 2017;130(16); 1857-1868.
92. Szczepanski MJ, Szajnik M, Welsh A, et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immu- nother. 2010;59(1):73-79.
93. Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.
94. Langenkamp U, Siegler U, Jorger S, et al. Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR- expressing natural killer cells. Haematologica. 2009;94(11):1590-1594.
95. Roy D-C, Walker I, Maertens J, et al. Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T- Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. Blood. 2018;132(Suppl 1):120.
96. Davies JK, Brennan LL, Wingard JR, et al. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018;24(17):4098-4109.
97. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673- 1683.
98. Merli P, Bertaina V, Galaverna F, et al. Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post- Allograft Infusion in Patients Given αβ T- Cell and B-Cell Depleted HLA- Haploidentical Allogeneic Stem Cell Transplantation (αβ haplo-HSCT) Contributing to Accelerate Immune Recovery. Blood. 2017;130(Suppl 1):211.
99. Research CfDEa. Approved Drugs - FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2018.
100.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26): 2531-2544.
101.Kebriaei P, Ciurea SO, Huls MH, et al. Pre- Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19⁺ Malignancies. Blood. 2015;126(23):862.
102.Liu J, Zhong JF, Zhang X, et al. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10 (1):35.
103.Radestad E, Wikell H, Engstrom M, et al. Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplanta- tion with HLA-matched related and unrelat- ed donors. J Immunol Res. 2014;2014: 578741.
104.Durer C, Durer S, Shafqat M, et al. Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post- Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia. Syst Rev. 2018;132:5742
105. Christopher MJ, Petti AA, Rettig MP, et al Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018;379(24):2330-2341.
106. Or R, Hadar E, Bitan M, et al. Safety and effi- cacy of donor lymphocyte infusions follow- ing mismatched stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12): 1295-1301.
58
haematologica | 2020; 105(1)